Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02660528 · ClinicalTrials.gov registry record · Phase 2
Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT02660528 is a Phase 2 study that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 3 participants.
The verdict
NCT02660528, a Phase 2 study, was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This proposed study sets out to examine the antidepressant effects of tocilizumab among patients with treatment-refractory major depression.
Interventions
- DRUG Tocilizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2016-04 |
| Est. Completion | 2020-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02660528
The ClinicalTrials.gov registry entry for NCT02660528 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tocilizumab is the first listed.
NCT02660528 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02660528 about?
NCT02660528 is a clinical study titled "Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder". This proposed study sets out to examine the antidepressant effects of tocilizumab among patients with treatment-refractory major depression.
What is the current status of trial NCT02660528?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2016-04. Estimated completion is 2020-06.
What interventions are being tested in trial NCT02660528?
The interventions under investigation include: Tocilizumab (DRUG).
Who is sponsoring clinical trial NCT02660528?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.